# US 2014/0154300 A1 · Methods and compositions for treatment of lesioned sites of body vessels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154300 A1
- Document ID: US20140154300A1
- Status: Published application
- Kind: A1
- Application number: 14/175,933
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2006-04-14
- Assignees: Abbott Cardiovascular Systems Inc.
- Applicants: Abbott Cardiovascular Systems Inc.
- Inventors: Florian Niklas Ludwig; Stephen Pacetti; Paul Consigny
- Web page: https://patentgrep.com/patent/US20140154300A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/44: Oxidoreductases (1)
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61L 2300/40: characterised by a specific therapeutic activity or mode of action
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.

## Claims

### Claim 1

A composition comprising:
an amount of an agent suitable for delivery into a body vessel wherein the agent directly or indirectly induces cell apoptosis at a lesioned site.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the agent is encapsulated within a carrier.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the agent is a nitric oxide source.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the nitric oxide source is selected from the group consisting of a nitric oxide gas, a nitric oxide solution or a nitric oxide derivative solution.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the agent is an amino acid.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the amino acid is L-arginine or a polypeptide of L-arginine.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the agent is adapted to inhibit arginase I or arginase II.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the agent further comprises:
a first agent; and
a second agent.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the first agent is selected from the group consisting of a nitric oxide-containing compound and L-arginine.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the second agent is selected from the group consisting of a compound suitable for reacting with the nitric oxide-containing compound and nitric oxide synthase.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the first agent and the second agent are encapsulated within a carrier.

### Claim 13 (depends on 9)

The composition of claim 9, wherein the first agent or the second agent is encapsulated within a carrier.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the carrier is selected from the group consisting of an implantable medical device, a microsphere, a nanoparticle, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the cell is at least one macrophage cell.

### Claim 17

A treatment kit comprising:
a nitric oxide source; and
a delivery device.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the nitric oxide source is encapsulated in a carrier.

### Claim 19 (depends on 17)

The kit of claim 17, wherein the nitric oxide source is selected from the group consisting of a nitric oxide gas, a nitric oxide solution, a nitric oxide composition and L-arginine.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the nitric oxide composition includes a first agent and a second agent.

### Claim 21 (depends on 20)

The kit of claim 20, wherein the first agent is selected from the group consisting of a nitric oxide-containing compound and L-arginine.

### Claim 22 (depends on 20)

The kit of claim 20, wherein the second agent is selected from the group consisting of a compound suitable for reacting with the nitric oxide-containing compound and nitric oxide synthase.

### Claim 23 (depends on 20)

The kit of claim 20, wherein the first agent and the second agent are encapsulated within a carrier.

### Claim 24 (depends on 20)

The kit of claim 20, wherein the first agent or the second agent is encapsulated within a carrier.

### Claim 25 (depends on 23)

The kit of claim 23, wherein the carrier is selected from the group consisting of an implantable medical device, microspheres, nanoparticles, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot.

### Claim 26 (depends on 24)

The kit of claim 24, wherein the carrier is selected from the group consisting of an implantable medical device, microspheres, nanoparticles, a gel, a gel depot, a hydrogel, a hydrogel depot, a polymer and a polymer depot.

### Claim 27 (depends on 17)

The kit of claim 17, wherein the delivery device is a catheter assembly.